



OnDemand: TOS 43rd Annual Scientific Meeting Continuing Medical Education Information for Learners

Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of 78 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ACCME Activity ID 203385711

Important Dates for On-Demand Course (Enduring Material)

Date of Release: January 15, 2026

Date of Termination: December 31, 2026

Learning Objectives

1. Apply the latest recommendations for evaluation and treatment; tailor intervention strategies based on patient characteristics such as age or metabolic or behavioral phenotype; recognize the differences between weight loss and weight loss maintenance.
2. Understand the evidence-based science regarding neuroendocrine, environmental, endocrine, microbiota and/or cognitive behavioral mechanisms regulating energy balance and body weight. Apply that knowledge to develop and

implement treatment options for adults and pediatric patients with overweight, obesity or obesity-related comorbidities.

3. Implement appropriate strategies for diagnosing adolescent and pediatric obesity, evaluate current treatment options and emerging therapeutics and provide care and treatment to adolescent and pediatric patients accordingly. Teach evidence-based strategies for obesity prevention in the pediatric and adolescent population.
4. Apply lessons learned about the impact of nutrition and obesity initiatives and policies to reduce health disparities and stigmatization of individuals with obesity.
5. Apply new knowledge related to obesity treatment options from the perspectives of Metabolism and Integrative Physiology, Neuroscience, Intervention and Clinical Studies, Population Health, Clinical/Professional Practice, and Policy/Public Health.
6. Incorporate knowledge about clinical practice management among health care providers to support their ability to treat the underlying disease obesity and its complications.

Commercial Support

This enduring material of the live meeting received no commercial support from any ACCME defined ineligible company.

Faculty and Planning Committee Disclosure Information

The Obesity Society adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities¹ (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

The Obesity Society asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with ineligible companies. This information is disclosed to CME activity participants. The Obesity Society has procedures to mitigate all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals or devices is being discussed. In the list below, the nature of the relationship and company are followed by the industry of that company.

Chairs:

At TOS activities, course/session chairs are responsible for timekeeping, introductions, housekeeping announcements, and presenting audience questions to speakers. TOS has determined that chairs do not have the ability to influence

¹ An ineligible company as defined by the ACCME is one that is not eligible for ACCME accreditation, in other words those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include: 1) Advertising, marketing, or communication firms whose clients are ineligible companies, 2) Bio-medical startups that have begun a governmental regulatory approval process, 3) Compounding pharmacies that manufacture proprietary compound, 4) Device manufacturers or distributors, 5) Diagnostic labs that sell proprietary products, 6) Growers, distributors, manufacturers or sellers of medical foods and dietary supplements, 7) Manufacturers of health-related wearable products, 8) Pharmaceutical companies or distributors, 9) Pharmacy benefit managers, 10) Reagent manufacturers or sellers. Reference: <https://accme.org/faq/what-accmes-definition-ineligible-company>

content. Accordingly, TOS does not collect, mitigate, or disclose relevant financial relationships of chairs (unless they have a dual role as a planner or speaker).

Panelists and Speakers:

Panelists are speakers who speak without presenting slides in a portion of a session or course. As speakers, they are required to disclose, and their relevant financial relationships are listed below. All speakers - with or without relevant financial relationships, with or without slides - are advised, and subsequently attest that “The content and/or presentation of the information with which I am involved will promote quality or improvements in health care and will not promote a specific proprietary business interest or a commercial interest (including ACCME-defined ineligible companies). Content for this activity, including any presentation of therapeutic options, will be balanced, evidence-based and commercially unbiased.”

Speaker Disclosures:

| First Name | Last Name | Disclosures |
|------------|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ziyad | Al-Aly | No Relevant Financial Relationships |
| Lydia | Alexander | Advisor relationship with Novo Nordisk (Pharmaceuticals). Consultant relationship with Amgen (Pharmaceuticals). Speaker relationship with Eli Lilly (Pharmaceuticals). |
| Timothy | Allerton | No Relevant Financial Relationships |
| Jaime | Almandoz | Advisor relationship with AbbVie (Pharmaceuticals), Amgen (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Kailera (Pharmaceuticals), Metsera (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), Rhythm (Pharmaceuticals), and Rivus (Pharmaceuticals). |
| Amin | Amin | No Relevant Financial Relationships |
| Michaela | Anderson | Researcher relationship with United Therapeutics (Pharmaceuticals). |
| Jamy | Ard | Advisor relationship with Amgen (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), and Weight Watchers (Medical Food). Consultant relationship with Eli Lilly (Pharmaceuticals), Intuitive (Medical Device), Nestle Healthcare Nutrition (Medical Food), Regeneron (Pharmaceuticals), and WeightWatchers (Medical Food). In-Kind Support relationship with KVKTech (Pharmaceuticals), Nestle Healthcare Nutrition (Medical Food), and Weight Watchers (Medical Food). Researcher relationship with Amgen (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Epitomee (Medical Device), KVKTech (Pharmaceuticals), and WeightWatchers (Medical Food). |
| Sarah | Armstrong | No Relevant Financial Relationships |

| | | |
|-------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Louis | Aronne | <p>Advisor relationship with Altimmune (Pharmaceuticals), Atria (Biomedical), Boehringer-Ingelheim (Biomedical), CinFina Pharma (Pharmaceuticals), Corteria (Pharmaceuticals), Eli Lilly (Pharmaceuticals), MBX Bioscience (Biomedical), Jamieson Wellness (Pharmaceuticals), Janssen (Pharmaceuticals), Juvena Therapeutics (Pharmaceuticals), Kallyope (Biomedical), Pfizer (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), Senda Biosciences (Biomedical), Skye Bio (Biomedical), Syntis Bio (Biomedical), Verdiva Bio (Biomedical), Versanis (Biomedical), and Zealand (Pharmaceuticals).</p> <p>Consultant relationship with Carmot Therapeutics (Biomedical), Currax Pharma (Pharmaceuticals), Enterin (Biomedical), Helicore Biopharma (Biomedical), Metsera (Biomedical), Morphic Medic / GI Dynamics (Medical Device), Novartis (Pharmaceuticals), Prosciento (Digital Health Platform), Summit Clinical (Clinical Research Platform), and Veru (Pharmaceuticals).</p> <p>Stock Options relationship with ERX (Pharmaceuticals), Kallyope (Biomedical), MBX Bioscience (Biomedical), Metsera (Biomedical), Skye Bio (Biomedical), Syntis Bio (Biomedical), Verdiva Bio (Biomedical), and Veru (Pharmaceuticals).</p> <p>Researcher relationship with AstraZeneca (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Jamieson Wellness (Pharmaceuticals), Janssen (Pharmaceuticals), Novo Nordisk (Pharmaceuticals).</p> |
| Dan | Azagury | Advisor relationship with Endolumik (Medical Device), Form Health (Services), GI Windows (Medical Device), and Moon Surgical (Medical Device). |
| Sarah | Barenbaum | No Relevant Financial Relationships |
| Jessica | Bartfield | No Relevant Financial Relationships |
| John | Batsis | Consultant relationship with Regeneron (Pharmaceuticals). |
| Heidi | Bednarchuk | No Relevant Financial Relationships |
| Daniel | Bessesen | Researcher relationship with Eli Lilly (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), and Pfizer (Pharmaceuticals). |
| Lisa | Beutler | <p>Advisor relationship with Zealand Pharma (Pharmaceuticals).</p> <p>Stock relationship with Eli Lilly (Pharmaceuticals).</p> |
| Mitch | Biermann | Researcher relationship with Eli Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals). |
| Tung | Bui | No Relevant Financial Relationships |
| Kyle | Burger | No Relevant Financial Relationships |
| E. Thomaseo | Burton | No Relevant Financial Relationships |
| Omni | Cassidy | No Relevant Financial Relationships |
| Kacey | Chae | No Relevant Financial Relationships |
| Ariana | Chao | Advisor relationship with Boehringer Ingelheim (Pharmaceuticals), Eli Lilly and Company (Pharmaceuticals), and Novo Nordisk (Pharmaceuticals). |

| | | |
|--------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | Researcher relationship with Eli Lilly and Company (Pharmaceuticals). |
| Zoobia | Chaudhry | No Relevant Financial Relationships |
| Alissa | Chen | No Relevant Financial Relationships |
| Lawrence | Cheskin | Consultant relationship with Aardvark Therapeutics (Pharmaceuticals). Stock relationship with Aardvark Therapeutics (Pharmaceuticals). |
| Karan | Chhabra | Consultant relationship with GI Windows Surgical, LLC (Medical Device). |
| Shradha | Chhabria | No Relevant Financial Relationships |
| Benjamin | Chrisinger | No Relevant Financial Relationships |
| John | Clark | No Relevant Financial Relationships |
| Stephen | Cook | No Relevant Financial Relationships |
| Sarah | Corapi | No Relevant Financial Relationships |
| Marc-Andre | Cornier | Advisor relationship with Biophytis (Biomedical), Eli Lilly (Pharmaceuticals), Keros (Biomedical), Pfizer (Pharmaceuticals), Wave (Biomedical), and Zyversa (Biomedical). Consultant relationship with AstraZeneca (Pharmaceuticals). Data safety monitoring board relationship with Advarra (Pharmaceuticals). Researcher relationship with Amgen (Pharmaceuticals), Cleery (Biomedical), Ionis (Pharmaceuticals), Kaneka (Medical Device), and Novartis (Pharmaceuticals). |
| Florina | Corpodean | No Relevant Financial Relationships |
| David | Creel | No Relevant Financial Relationships |
| Javed Ahamed | Cumbum Syed | No Relevant Financial Relationships |
| David | Cummings | No Relevant Financial Relationships |
| Mariane | De Oliveira | No Relevant Financial Relationships |
| Lea | Decarie-Spain | No Relevant Financial Relationships |
| Fereshteh | Dehghani | No Relevant Financial Relationships |
| Dimpi | Desai | No Relevant Financial Relationships |
| Wiebke | Diederich | No Relevant Financial Relationships |
| Alexandra | DiFeliceantonio | No Relevant Financial Relationships |
| Manuel | Dote Montero | No Relevant Financial Relationships |
| Carol | Duh-Leong | No Relevant Financial Relationships |
| Roxanne | Dupuis | No Relevant Financial Relationships |
| Cara | Ebbeling | No Relevant Financial Relationships |

| | | |
|-----------|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Robert | Eckel | <p>Advisor relationship with Arrowhead (Pharmaceuticals), Madrigal (Pharmaceuticals), and Novo Nordisk (Pharmaceuticals).</p> <p>Consultant relationship with Amgen (Pharmaceuticals), Regeneron (Pharmaceuticals), Tolmar (Pharmaceuticals), and UpToDate (Biomedical).</p> <p>Speaker relationship with 89bio (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Ionis (Pharmaceuticals), New Amsterdam (Pharmaceuticals), and Viatrix (Pharmaceuticals).</p> |
| Leonard | Egede | No Relevant Financial Relationships |
| Alejandra | Ellison-Barnes | No Relevant Financial Relationships |
| Joel | Elmqvist | Researcher relationship with Regeneron Pharmaceutical (Pharmaceuticals). |
| William | Evans | No Relevant Financial Relationships |
| Anthony | Ferrante | Researcher relationship with Boehringer-Ingelheim (Pharmaceuticals). |
| Lauren | Fiechtner | No Relevant Financial Relationships |
| Allon | Friedman | <p>Advisor relationship with Eli Lilly (Pharmaceuticals), Gila Therapeutics (Biomedical), Morphic Medical (Medical Device), and Novo Nordisk (Pharmaceuticals).</p> <p>Site PI for clinical trial relationship with Eli Lilly (Biomedical).</p> |
| Jeffrey | Friedman | <p>Royalties or Patent Beneficiary relationship with Chiesi (Pharmaceuticals).</p> <p>Stock relationship with Eli Lilly (Pharmaceuticals).</p> |
| Christine | Gallagher | Researcher relationship with Altimmune (Pharmaceuticals), Amgen (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), Currax (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Found (Weight Management), Novo Nordisk (Pharmaceuticals), Pfizer (Pharmaceuticals), Structure Therapeutics (Pharmaceuticals), Wave Life Sciences (Pharmaceuticals), and Weight Watchers (Medical Food). |
| Adam | Gilden | Researcher relationship with Eli Lilly (Pharmaceuticals). |
| Ayush | Giri | No Relevant Financial Relationships |
| Victoria | Goldman | No Relevant Financial Relationships |
| Rachel | Goode | No Relevant Financial Relationships |
| Alyson | Goodman | No Relevant Financial Relationships |
| Carlos | Grilo | No Relevant Financial Relationships |
| Anna | Grummon | No Relevant Financial Relationships |

| | | |
|-------------|--------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Kirk | Habegger | Advisor relationship with Advance Therapeutics (Pharmaceuticals) and Boehringer Ingelheim (Pharmaceuticals). Consultant relationship with Genuiti Therapeutics (Pharmaceuticals) and Glyscend (Medical Device). Researcher relationship with Eli Lilly (Pharmaceuticals). Stock Options relationship with Glyscend (Medical Device). |
| Sajal Kumar | Halder | No Relevant Financial Relationships |
| Kevin | Hall | Consultant relationship with AstraZeneca (Pharmaceuticals), MacroFirst (Medical Device), and WW (Medical Food). |
| Tanya | Halliday | No Relevant Financial Relationships |
| C. | Hatton | No Relevant Financial Relationships |
| Keally | Haushalter | No Relevant Financial Relationships |
| Faith Anne | Heeren | Consultant relationship with Weight Watchers (Medical Food). In-Kind Support relationship with American Academy of Pediatrics (Science). |
| Erin | Hennessy | No Relevant Financial Relationships |
| Trent | Herda | No Relevant Financial Relationships |
| Emily | Hill | No Relevant Financial Relationships |
| James | Hill | Advisor relationship with General Mills (Food). |
| Caroline | Himbert | No Relevant Financial Relationships |
| Jay | Horton | Advisor relationship with Merck (Pharmaceuticals). Consultant relationship with Abbvie (Pharmaceuticals), Aqur Biosciences (Pharmaceuticals), LG Chem Life Sciences Innovation Center (Pharmaceuticals), Pfizer (Pharmaceuticals), and Regeneron (Pharmaceuticals). |
| Daniel | Hsia | Advisor relationship with Eli Lilly and Company (Pharmaceuticals). |
| Sophia | Hua | No Relevant Financial Relationships |
| Zach | Hutelin | No Relevant Financial Relationships |
| Jennifer | Hwang | No Relevant Financial Relationships |
| Talat | Ikizler | Speaker relationship with Fresenius Kabi (Biomedical). |
| Kellene | Isom | No Relevant Financial Relationships |
| Valentina | Ivezaj | Consultant relationship with Optum (Biomedical). |
| Yu Mi | Kang | No Relevant Financial Relationships |
| Harsha | Karanchi | No Relevant Financial Relationships |
| Ju Hee | Kim | No Relevant Financial Relationships |
| Samuel | Klein | Advisor relationship with Altimmune (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), and Merck (Pharmaceuticals). Consultant relationship with Alnylam (Pharmaceuticals). |
| Alicia | Kunin-Batson | No Relevant Financial Relationships |

| | | |
|----------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Robert | Kushner | <p>Advisor relationship with Abbvie (Pharmaceuticals), Antag (Pharmaceuticals), Astra Zeneca (Pharmaceuticals), Currax (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), and WW (Medical Food).</p> <p>Consultant relationship with Altimune (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), Regeneron (Pharmaceuticals), and Structure (Pharmaceuticals).</p> |
| Ian | Lanza | No Relevant Financial Relationships |
| Tashara | Leak | No Relevant Financial Relationships |
| David | Lefer | No Relevant Financial Relationships |
| Dominick | Lemas | No Relevant Financial Relationships |
| Kristina | Lewis | <p>Advisor relationship with NovoNordisk (Pharmaceuticals).</p> <p>NIH funded trial relationship with KVK Tech (Pharmaceuticals).</p> |
| Soo | Lim | <p>Advisor relationship with CKD (Pharmaceuticals).</p> <p>Speaker relationship with AstraZeneca (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), Daewoong (Pharmaceuticals), Eli Lilly (Pharmaceuticals), GSK (Pharmaceuticals), LG Chem (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), and Servier (Pharmaceuticals).</p> |
| Kate | Lofgren | No Relevant Financial Relationships |
| Michelle | Look | <p>Advisor relationship with Boehringer Ingelheim (Pharmaceuticals), Eli Lilly (Pharmaceuticals), and Novo Nordisk (Pharmaceuticals).</p> <p>Speaker relationship with Eli Lilly (Pharmaceuticals).</p> |
| Janet | Lydecker | No Relevant Financial Relationships |
| Gina | Many | No Relevant Financial Relationships |
| Corby | Martin | <p>Advisor relationship with EHE Health (Health Care Provider) and Wondr Health (Weight Management).</p> <p>Consultant relationship with Almond Board of California (Food), Medifast (Medical Food), and Zealand Pharma (Pharmaceuticals).</p> <p>Researcher relationship with Boehringer Ingelheim (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), Spoonified (Food), and WW (Medical Food).</p> <p>Royalties or Patent Beneficiary relationship with Access Business Group (Weight Management).</p> |
| Susan | McElroy | <p>Consultant relationship with Axsome (Pharmaceuticals), Idorsia (Pharmaceuticals), Kallyope (Pharmaceuticals), Levo (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), Otsuka (Pharmaceuticals), Soleno (Pharmaceuticals), and Sunovion (Pharmaceuticals).</p> |

| | | |
|-----------|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | Researcher relationship with Axsome (Pharmaceuticals), Neurocrine (Pharmaceuticals), and Otsuka (Pharmaceuticals). |
| David | Mendoza | No Relevant Financial Relationships |
| Daniel | Mensah | No Relevant Financial Relationships |
| Abigail | Metzler | No Relevant Financial Relationships |
| Jaime | Moore | No Relevant Financial Relationships |
| Aviva | Musicus | No Relevant Financial Relationships |
| Kalpana | Muthusamy | Researcher relationship with Endogenex (Biomedical) and Regeneron (Pharmaceuticals). |
| Mandar | Muzumdar | No Relevant Financial Relationships |
| Chiadi | Ndumele | No Relevant Financial Relationships |
| Linhda | Nguyen | Consultant relationship with Novo Nordisk (Pharmaceuticals). |
| Yan | Ni | No Relevant Financial Relationships |
| Sally | Omidvar | No Relevant Financial Relationships |
| Stephen | O'Rahilly | Advisor relationship with Marea Therapeutics (Pharmaceuticals) and Pfizer (Pharmaceuticals). Stock Options relationship with Marea Therapeutics (Pharmaceuticals). Researcher relationship with GSK (Pharmaceuticals). |
| Babak | Orandi | Advisor relationship with Boehringer Ingelheim (Pharmaceuticals). |
| Chigolum | Oyeka | No Relevant Financial Relationships |
| Matthew | Paponetti | No Relevant Financial Relationships |
| Megan | Parker | No Relevant Financial Relationships |
| Elizabeth | Parks | Advisor relationship with Simply Good (Food). Consultant relationship with Corcept (Pharmaceuticals). |
| Robyn | Pashby | No Relevant Financial Relationships |
| Michele | Patel | No Relevant Financial Relationships |
| Elizabeth | Paul | Advisor relationship with Boehringer Ingelheim (Pharmaceuticals) and Pfizer (Pharmaceuticals). Speaker relationship with AmGen (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Genetech (Pharmaceuticals), and Structure Therapeutics (Pharmaceuticals). |
| Nicole | Pearce | No Relevant Financial Relationships |
| Anna | Pendrey | No Relevant Financial Relationships |
| Joshua | Petimar | No Relevant Financial Relationships |
| Cash | Petree | No Relevant Financial Relationships |
| Paolo | Piaggi | No Relevant Financial Relationships |
| Michael | Ponte | No Relevant Financial Relationships |
| Barry | Popkin | No Relevant Financial Relationships |
| Lisa | Powell | No Relevant Financial Relationships |

| | | |
|-----------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Carla | Prado | Consultant relationship with Nutricia (Medical Food). Speaker relationship with Abbott Nutrition (Medical Food), Nestle Health Sciences (Medical Food), and Novo Nordisk (Pharmaceuticals). |
| Rhonda | Pruitt | No Relevant Financial Relationships |
| Rana | Pullatt | Speaker relationship with Conmed (Medical Device), Intuitive Surgical (Medical Device), and Medtronic (Medical Device). |
| Jonathan | Purnell | Advisor relationship with Boehringer Ingelheim (Pharmaceuticals) and Luciole (Pharmaceuticals). Consultant relationship with Novo Nordisk (Pharmaceuticals) and Regeneron (Pharmaceuticals). Research Grant Funding Support relationship with NICHD/NIH (Government). |
| Nancy | Puzziferri | Advisor relationship with NovoNordisk (Pharmaceuticals). |
| Ritika | Raghavan | No Relevant Financial Relationships |
| Johanna | Ralston | No Relevant Financial Relationships |
| Erika | Rees-Punia | No Relevant Financial Relationships |
| Evan | Reynolds | No Relevant Financial Relationships |
| Angela | Ritten | Speaker relationship with Currax (Pharmaceuticals) and Lilly (Pharmaceuticals). |
| Renee | Rogers | Advisor relationship with AstraZeneca (Pharmaceuticals). Consultant relationship with Wondr Health (Weight Management). Educational relationship with Seca (Medical Device). |
| Barbara | Rolls | No Relevant Financial Relationships |
| Alexandra | Ross | No Relevant Financial Relationships |
| Michele | Rouse | No Relevant Financial Relationships |

| | | |
|----------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Donna | Ryan | <p>Advisor relationship with Abbvie (Pharmaceuticals), Altimmune (Pharmaceuticals), Amgen (Pharmaceuticals), AstraZeneca (Pharmaceuticals), Biohaven (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), Calibrate (Biomedical), Carmot (Pharmaceuticals), Cin RX (Pharmaceuticals), Currax (Pharmaceuticals), Eli Lilly (Pharmaceuticals), eMed (Biomedical), Epitomee (Medical Device), Nestle (Medical Food), Regeneron (Pharmaceuticals), Scientific Intake (Medical Device), Structure Therapeutics (Pharmaceuticals), Tenvie (Pharmaceuticals), Wondr Health (Biomedical), and Zealand (Pharmaceuticals).</p> <p>Consultant relationship with Source Bio (Pharmaceuticals).</p> <p>Data Monitoring Committee relationship with Cin RX (Pharmaceuticals) and Eli Lilly (Pharmaceuticals).</p> <p>Research relationship with Novo Nordisk (Pharmaceuticals).</p> <p>Speaker relationship with Eli Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals).</p> <p>Stock Options relationship with Epitomee (Medical Device) and Scientific Intake (Medical Device).</p> |
| Amin | Sabet | Stock relationship with Abbott Labs (Pharmaceuticals), AbbVie Inc (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Johnson & Johnson (Pharmaceuticals), Merck & Co (Pharmaceuticals), and Novo Nordisk (Pharmaceuticals). |
| Darleen | Sandoval | No Relevant Financial Relationships |
| Philipp | Scherer | No Relevant Financial Relationships |
| Laura | Schmidt | No Relevant Financial Relationships |
| Camille | Schneider-Worthington | No Relevant Financial Relationships |
| Jessica | Schwartz | Researcher relationship with Novo Nordisk (Pharmaceuticals). |
| Bruce | Scott | No Relevant Financial Relationships |
| Mireille | Serlie | Researcher relationship with Appo (Distributes parenteral nutrition and medication to patients), Novo Nordisk (Pharmaceuticals), and Takeda (Pharmaceuticals). |
| Lisa | Shank | No Relevant Financial Relationships |
| Amod | Sharma | No Relevant Financial Relationships |
| Arya | Sharma | <p>Advisor relationship with Abbvie (Pharmaceuticals), AstraZeneca (Pharmaceuticals), Bayer (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), Eli Lilly (Pharmaceuticals), and Novo Nordisk (Pharmaceuticals).</p> <p>Speaker relationship with Currax (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Novo Nordisk (Pharmaceuticals).</p> |
| Yun | Shen | No Relevant Financial Relationships |
| Sepideh | Sheybani Deluoui | No Relevant Financial Relationships |

| | | |
|----------|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Melissa | Shoemaker | No Relevant Financial Relationships |
| Karolina | Skibicka | No Relevant Financial Relationships |
| Lauren | Sparks | No Relevant Financial Relationships |
| Amanda | Staiano | No Relevant Financial Relationships |
| Fatima | Stanford | Advisor relationship with Apnimed (Biomedical), Boehringer Ingelheim (Pharmaceuticals), Calibrate (Weight Management), Clearmind Medicine (Pharmaceuticals), Currax (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Empros Pharma (Pharmaceuticals), Ilant Health (Biomedical), Lifeforce (Biomedical), Mellicell (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), Pfizer (Pharmaceuticals), and Vida Health (Biomedical). Consultant relationship with Astra Zeneca (Pharmaceuticals). |
| Matthew | Steinhauser | No Relevant Financial Relationships |
| Sarah | Stewart | No Relevant Financial Relationships |
| Paul | Stolin | No Relevant Financial Relationships |
| Marian | Tanofsky-Kraff | No Relevant Financial Relationships |
| Beverly | Tchang | Advisor relationship with Amgen (Pharmaceuticals), Boehringer-Ingelheim (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Metsera (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), Roche (Pharmaceuticals), Roman Health Ventures (Pharmaceuticals), Skye Bioscience (Pharmaceuticals), and Tern (Pharmaceuticals). Stock Options relationship with Roman Health Ventures (Pharmaceuticals). |
| Vidhu | Thaker | Independent Contractor relationship with Rhythm (Pharmaceuticals). Speaker relationship with Rhythm (Pharmaceuticals). |
| Arianne | Theiss | No Relevant Financial Relationships |
| Grant | Tinsley | Advisor relationship with Legion Athletics, Inc. (Supplement) and Prism Labs (Medical Device). Researcher relationship with Bunge Loders Croklaan (Supplement), EHP Labs (Supplement), Prism Labs (Medical Device), and Size Stream LLC (Medical Device). Royalties or Patent Beneficiary relationship with Metabolic Technologies (Supplement). Stock relationship with Altimmune (Pharmaceuticals), Globus Medical (Medical Device), and Prism Labs (Medical Device). |
| Deirdre | Tobias | Researcher relationship with Montai Health Inc (Biomedical). |
| Mabel | Toribio | Researcher relationship with Caristo (Biomedical) and Novartis (Pharmaceuticals). |
| Lisa | Tritto | No Relevant Financial Relationships |
| Ana | Valencia | No Relevant Financial Relationships |
| Krista | Varady | No Relevant Financial Relationships |

| | | |
|---------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amanda | Velazquez | Advisor relationship with Weight Watchers (Medical Food) Consultant relationship with Eli Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals). |
| Clay | Venetis | No Relevant Financial Relationships |
| Alison | Ventura | No Relevant Financial Relationships |
| Jose | Villamarin | No Relevant Financial Relationships |
| Rebekah | Walker | No Relevant Financial Relationships |
| Katie | Whytock | No Relevant Financial Relationships |
| Denise | Wilfley | No Relevant Financial Relationships |
| Kevin | Williams | Stock relationship with Eli Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals). |
| Hanieh | Yaghootkar | Researcher relationship with Calico Life Sciences (Biomedical). |
| Masha | Yemets | No Relevant Financial Relationships |
| Adnin | Zaman | No Relevant Financial Relationships |
| Tonya | Zeiger | No Relevant Financial Relationships |
| Evan | Zeitler | Consultant relationship with Novo Nordisk (Pharmaceuticals). |
| Jeffrey | Zigman | Stock relationship with Eli Lilly (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), and Medtronic (Medical Device). |

Planner Disclosures:

| First Name | Last Name | Role | Disclosure |
|------------|---------------|---------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Vance | Albaugh | T2: Neuroscience | Researcher relationship with Johnson & Johnson (Pharmaceuticals). Speaker relationship with Novo Nordisk (Pharmaceuticals). |
| Timothy | Allerton | T1: Metabolism/Integrative Physiology Chair | No Relevant Financial Relationships |
| Gretchen | Ames | T5: Clinical/Professional Practice | No Relevant Financial Relationships |
| John | Apolzan | T3: Intervention/Clinical Studies | No Relevant Financial Relationships |
| Julio | Ayala | T2: Neuroscience | No Relevant Financial Relationships |
| Katherine | Balantekin | T4: Population Health | No Relevant Financial Relationships |
| John | Batsis | T3: Intervention/Clinical Studies Chair | Consultant relationship with Regeneron (Pharmaceuticals). |
| Sherlyn | Celone-Arnold | TOS CEO starting 6/1/25 | No Relevant Financial Relationships |
| John | Clark | T6: Policy/Public Health Chair | No Relevant Financial Relationships |
| John | Cleek | T5: Clinical/Professional Practice Co-Chair | Speaker relationship with Eli Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals). |

| | | | |
|------------|----------|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Anthony | Comuzzie | TOS CEO until 5/30/25 | No Relevant Financial Relationships |
| Marc-Andre | Cornier | Liaison | <p>Advisor relationship with Biophytis (Biomedical), Eli Lilly (Pharmaceuticals), Keros (Biomedical), Pfizer (Pharmaceuticals), Wave (Biomedical), and Zyversa (Biomedical).</p> <p>Consultant relationship with AstraZeneca (Pharmaceuticals).</p> <p>Data safety monitoring board relationship with Advarra (Pharmaceuticals).</p> <p>Researcher relationship with Amgen (Pharmaceuticals), Cleery (Biomedical), Ionis (Pharmaceuticals), Kaneka (Medical Device), and Novartis (Pharmaceuticals).</p> |
| Tiffany | Cortes | T5: Clinical/Professional Practice | Researcher relationship with CJ-Cheil-Jedang-Corporation (Medical Supplement). |
| Lara | Dugas | T4: Population Health | No Relevant Financial Relationships |
| Mary | Evans | T4: Population Health Chair | No Relevant Financial Relationships |
| Jonathan | Flak | T2: Neuroscience Chair | Researcher relationship with Eli Lilly (Pharmaceuticals). |
| Laura | Goetz | T5: Clinical/Professional Practice Chair | No Relevant Financial Relationships |
| Barbara | Gower | T1: Metabolism/Integrative Physiology | Consultant relationship with Simply Good Foods (Food) |
| Anna | Grummon | T6: Policy/Public Health | No Relevant Financial Relationships |
| Kimberly | Gudzune | T3: Intervention/Clinical Studies | Advisor relationship with Eli Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals). |
| Ross | Hammond | T6: Policy/Public Health Co-Chair | No Relevant Financial Relationships |
| Deborah | Horn | T5: Clinical/Professional Practice | <p>Consultant relationship with Amgen (Pharmaceuticals), Astra Zeneca (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), and Zealand (Pharmaceuticals).</p> <p>Researcher relationship with Eli Lilly (Pharmaceuticals).</p> <p>Speaker relationship with Novo Nordisk (Pharmaceuticals).</p> |

| | | | |
|------------|-----------------|------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Daniela | Hurtado Andrade | T3: Intervention/Clinical Studies | Consultant relationship with Novo Nordisk (Pharmaceuticals). Researcher relationship with Endogenex (Biomedical) and Phenomix (Biomedical). |
| Maren | Laughlin | T1: Metabolism/Integrative Physiology | No Relevant Financial Relationships |
| E. Matthew | Morris | T1: Metabolism/Integrative Physiology | Stock relationship with Abbott Laboratories (Biomedical), Eli Lilly (Pharmaceuticals), Johnson & Johnson (Pharmaceuticals), Merck (Pharmaceuticals), and Novartis (Pharmaceuticals). |
| Ana | Palacios | T6: Policy/Public Health | Researcher relationship with Weight Watchers (Medical Food). |
| Alpa | Patel | T4: Population Health | No Relevant Financial Relationships |
| Joshua | Petimar | T6: Policy/Public Health | No Relevant Financial Relationships |
| Sebastian | Salathe | T1: Metabolism/Integrative Physiology | No Relevant Financial Relationships |
| Robert | Siegel | T4: Population Health Co-Chair | No Relevant Financial Relationships |
| Joseph | Skelton | T3: Intervention/Clinical Studies Co-Chair | No Relevant Financial Relationships |
| John | Thyfault | Co-Chair | No Relevant Financial Relationships |
| Kristy | Townsend | T2: Neuroscience | No Relevant Financial Relationships |
| Saroja | Voruganti | T1: Metabolism/Integrative Physiology Co-Chair | No Relevant Financial Relationships |
| Kevin | Williams | T2: Neuroscience Co-Chair | Stock relationship with Eli Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals). |
| Susan | Yanovski | Chair | No Relevant Financial Relationships during conference planning. Added Speaker relationship with Eli Lilly in July 2025. |

Reviewer Disclosures: No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

Bibliography

1. <https://www.annualreviews.org/content/journals/10.1146/annurev-pharmtox-031124-101146>
Ariana M. Chao¹, Simeon Taylor², Molly Moore³, Anastassia Amaro⁴, and Thomas A. Wadden³; Evolving Approaches for Pharmacological Therapy of Obesity; Vol. 65:169-189 (Volume publication date January 2025)
2. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery [published correction appears in *Obes Surg.* 2022 Nov 29;:]. *Obes Surg.* 2023;33(1):3-14. doi:10.1007/s11695-022-06332-1
3. CM Apovian “The Obesity Epidemic – Understanding the Disease and the Treatment.” *N Engl J Med* 2016; 374:177-179

4. PR Schauer et al "Bariatric Surgery versus Intensive medical therapy for Diabetes - 5-year outcomes." *N Engl J Med* 2017; 376:641-651
5. JS Yeh et al. "Obesity and Management of Weight Loss." *N Engl J Med* 2016; 375:1187-1189
6. E LeBlanc, C Patnode, E Webber, et al "Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults Updated Evidence Report and Systematic Review for the US Preventive Services Task Force." *JAMA*. 2018;320(11):1172-1191 doi:10.1001/jama.2018.7777
7. The physiological control of eating: signals, neurons, and networks. Watts AG, Kanoski SE, Sanchez-Watts G, Langhans W. *Physiol Rev*. 2022 Apr 1;102(2):689-813. doi: 10.1152/physrev.00028.2020. Epub 2021 Sep 6. PMID: 34486393
8. Functions of Interoception: From Energy Regulation to Experience of the Self. Quigley KS, Kanoski S, Grill WM, Barrett LF, Tsakiris M. *Trends Neurosci*. 2021 Jan;44(1):29-38. doi: 10.1016/j.tins.2020.09.008. PMID: 33378654
9. Louis J Aronne 1, Kevin D Hall 2, John M Jakicic 3, Rudolph L Leibel 4, Michael R Lowe 5, Michael Rosenbaum 4, Samuel Klein 6 "Describing the Weight-Reduced State: Physiology, Behavior, and Interventions". *Obesity (Silver Spring)*. 2021 Apr;29 Suppl 1(Suppl 1):S9-S24. doi: 10.1002/oby.23086.
10. SB Heymsfield and TA Wadden "Mechanisms, Pathophysiology, and Management of Obesity." *N Engl J Med* 2017;376:254-266
11. MW Schwartz, RJ Seeley, LM Zeltser, A Drewnowski, E Ravussin, LM Redman, RL Leibel "Obesity Pathogenesis." *Endocr Rev*. 2017 Aug 1;38(4):267-296.
12. AG Tsai et al, "Evidence of a Gap in Understanding, Obesity Among Physicians." *Obesity, Science and Practice Online* 1/12/18, DOI: 10/1002/asp4.416
13. MacLean PS, Rothman AJ, Nicastro HL, Czajkowski SM, Agurs-Collins T, Rice EL, Courcoulas AP, Ryan DH, Bessesen DH, Loria CM. The Accumulating Data to Optimally Predict Obesity Treatment (ADOPT) Core Measures Project: Rationale and Approach. *Obesity (Silver Spring)*. 2018 Apr;26 Suppl 2:S6-S15. doi: 10.1002/oby.22154.
14. Hampl SE, Hassink SG, Skinner AC, et al. "Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity" [published online ahead of print, 2023 Jan 9]. *Pediatrics*. 2023;e2022060640. doi:10.1542/peds.2022-060640.
15. [https://www.thelancet.com/journals/landia/article/PIIS2213-8587\(22\)00047-X/fulltext](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00047-X/fulltext)
16. Hiba Jebeile, PhDa,b · Prof Aaron S Kelly, PhDd · Grace O'Malley, PhD,e,f · Prof Louise A Baur, PhD; Obesity in children and adolescents: epidemiology, causes, assessment, and management; Volume 10, Issue 5p351-365, May 2022
17. US Preventive Services Task Force, Nicholson WK, Silverstein M, et al. Interventions for High Body Mass Index in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. *JAMA* 2024; 332:226.
18. O'Connor EA, Evans CV, Henninger M, et al. Interventions for Weight Management in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA* 2024; 332:233.
19. Heerman WJ, Rothman RL, Sanders LM, et al. A Digital Health Behavior Intervention to Prevent Childhood Obesity: The Greenlight Plus Randomized Clinical Trial. *JAMA* 2024; 332:2068.
20. Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. *Pediatrics*. 2023;151(2): e2022060640
21. J Pratt, A Browne, N Browne, M Bruzoni, M Cohen, A Desai, T Inge, B Linden, S Mattar, M Michalsky, D Podkammeni, K Reichard, F Cody Stanford, M Zeller, J Zitsman "ASMBS Pediatric Metabolic and Bariatric Surgery Guidelines,2018" *Surgery for Obesity and Related Diseases* 2018: 14: 882-901.
22. G Srivastava, C Fox, A Kelly, A Jastreboff, A Browne, N Browne, J Pratt, C Bolling, M Michalsky, S Cook, C Lenders, C Apovian "Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity" *Obesity* 24 Jan 2019: 27: 190-204.
23. Cardel M, Jastreboff AM, Kelly A. Treatment of Adolescent Obesity in 2020. *JAMA Insights*. 2019 September 30.

24. Talumaa, B., Brown, A., Batterham, R. L., & Kalea, A. Z. (2022). Effective strategies in ending weight stigma in healthcare. *Obesity Reviews*, 23(10), e13494.
25. Puhl, R. M., Himmelstein, M. S., & Pearl, R. L. (2020). "Weight stigma as a psychosocial contributor to obesity". *American Psychologist*, 75(2), 274–289. <https://doi.org/10.1037/amp0000538>
26. Pamela L Thornton 1, Shiriki K Kumanyika 2, Edward W Gregg 3, Maria R Araneta 4, Monica L Baskin 5, Marshall H Chin 6, Carlos J Crespo 7, Mary de Groot 8, David O Garcia 9, Debra Haire-Joshu 10, Michele Heisler 11, Felicia Hill-Briggs 12, Joseph A Ladapo 13, Nangel M Lindberg 14, Spero M Manson 15, David G Marrero 16, Monica E Peek 6, Alexandra E Shields 17, Deborah F Tate 18, Carol M Mangione 19 "New research directions on disparities in obesity and type 2 diabetes" 2020 Feb;1461(1):5-24. doi: 10.1111/nyas.14270. Epub 2019 Dec 3.
27. AcQasim, M Turcotte, RJ de Souza, MC Samaan, D Champredon, J Dushoff, JR Speakman, D Meyre "On the origin of obesity: identifying the biological, environmental and cultural drivers of genetic risk among human populations." *Obes Rev*. 2018 Feb;19(2):121-149.
28. N Hayba, SR Partridge, MM Nour, A Grech, M Allman Farinelli "Effectiveness of lifestyle interventions for preventing harmful weight gain among young adults from lower socioeconomic status and ethnically diverse backgrounds: a systematic review." *Obes Rev*. 2017 Nov 26.
29. GC Porter, K Laumb, T Michaud, F Brito, D Petreca, G Schwieger, T Bartee, KHK Yeary, PA Estabrooks "Understanding the impact of rural weight loss interventions: A systematic review and meta-analysis." *Obes Rev*. 2019 Jan 11. doi: 10.1111/obr.12825.
30. G Chen, A Doumatey, J Zhou, L Lei, A Bentley, O Fasanmade, G Okafor, B Eghan Jr, K Agyenim-Boateng, A Amoah, C Adebamowo, J Acheampong, T Johnson, J Oli, D Shriner, A Adeyemo, and C Rotimi1 "Genome-wide analysis identifies an African- specific variant in SEMA4D that is associated with Body Mass Index." *Obesity* 2017 April ; 25(4): 794–800. doi:10.1002/oby.21804.
31. National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Food and Nutrition Board, Roundtable on Obesity Solutions. "The Challenge of Treating Obesity and Overweight: Proceedings of a Workshop." Washington (DC): National Academies Press (US); 2017 Dec 21.
32. SB Heymsfield and TA Wadden "Mechanisms, Pathophysiology, and Management of Obesity." *N Engl J Med* 2017;376:254-266
33. JS Yeh et al. "Obesity and Management of Weight Loss." *N Engl J Med* 2016; 375:1187-1189
34. DA Williamson "Fifty Years of Behavioral/Lifestyle Interventions for Overweight and Obesity: Where Have We Been and Where Are We Going?" *Obesity (Silver Spring)*. 2017 Nov;25(11):1867-1875.
35. E LeBlanc, C Patnode, E Webber, et al "Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults Updated Evidence Report and Systematic Review for the US Preventive Services Task Force." *JAMA*. 2018;320(11):1172-1191. doi:10.1001/jama.2018.7777
36. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. *The New England Journal of Medicine*, 387(3), July 21, 2022.
37. Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., Ahmad, N. N., & Forrester, T. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. *Nature Medicine*, 29, 2909–2918. Published online: 15 October 2023. <https://doi.org/10.1038/s41591-023-02597-w>
38. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F., for the STEP 1 Study Group. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. *The New England Journal of Medicine*, 384(11), 989-1002. DOI: 10.1056/NEJMoa2032183

39. Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., Ahmad, N. N., & Forrester, T. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. *Nature Medicine*, 29, 2909–2918. Published online: 15 October 2023. <https://doi.org/10.1038/s41591-023-02597-w>
40. Elmaleh-Sachs A, et al. Obesity Management in Adults: A Review. *JAMA* 2023; 330(20):2000-15. PMID: 38015216.
41. DE Wilfley, AE Staiano, M Altman, J Lindros, A Lima, SG Hassink, WH Dietz, S Cook “Improving Access and Systems of Care for Evidence-Based Childhood Obesity Treatment Conference Workgroup.” *Obesity* (Silver Spring). 2017 Jan;25(1):16-29.
42. C Baum, K Andino, E Wittbrodt, S Stewart, K Szymanski, R Turpin “The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA” *Pharmacoeconomics*. 2015 Jul;33(7):643-53.
43. AS Chawla, CW Hsiao, MC Romney, R Cohen, F Rubino, P Schauer, P Cremieux “Gap Between Evidence and Patient Access: Policy Implications for Bariatric and Metabolic Surgery in the Treatment of Obesity and its Complications.” *Pharmacoeconomics*. 2015 Jul;33(7):629-41.
44. N Jannah, J Hild, C Gallagher, and W Dietz "Coverage for Obesity Prevention and Treatment Services: Analysis of Medicaid and State Employee Health Insurance Programs" *Obesity* 2018 Dec; 26(12): 1834-1840.
45. Salminen P, et al. IFSO Consensus on Definitions and Clinical Practice Guidelines for Obesity Management-an International Delphi Study. *Obes Surg*. 2024; 34(1): 30-42. PMID: 37999891.

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability, or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

This document was last updated January 15, 2026.